Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.
…
continue reading
Content provided by BMJ talk medicine and BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ talk medicine and BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Post-PARP Myeloid Neoplasms with Giuseppe Caruso
MP3•Episode home
Manage episode 362734900 series 1426075
Content provided by BMJ talk medicine and BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ talk medicine and BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso discuss post-PARP myeloid neoplasms. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) under the mentorship of Professor Nicoletta Colombo and has now started his research fellowship period at Mayo Clinic (Rochester) under the supervision of Professor William Cliby. His main interest areas are gynecologic oncology, personalized oncology, and clinical research. Highlights: - Myeloid neoplasms post PARPi in patients with ovarian cancer are gradually emerging as life-threatening late toxicities and should not be underestimated. - The first two years of PARPi exposure are the critical window of onset and persistent cytopenia has been recognized as an early warning sign. - Active surveillance, differential diagnosis, and prompt hematological referral are crucial. - PARPi are recommended in the first line also to improve the risk-benefit ratio. - PARPi should be used cautiously in patients with a higher baseline risk and/or those who are less likely to have a significant benefit.
…
continue reading
4250 episodes
MP3•Episode home
Manage episode 362734900 series 1426075
Content provided by BMJ talk medicine and BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ talk medicine and BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso discuss post-PARP myeloid neoplasms. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) under the mentorship of Professor Nicoletta Colombo and has now started his research fellowship period at Mayo Clinic (Rochester) under the supervision of Professor William Cliby. His main interest areas are gynecologic oncology, personalized oncology, and clinical research. Highlights: - Myeloid neoplasms post PARPi in patients with ovarian cancer are gradually emerging as life-threatening late toxicities and should not be underestimated. - The first two years of PARPi exposure are the critical window of onset and persistent cytopenia has been recognized as an early warning sign. - Active surveillance, differential diagnosis, and prompt hematological referral are crucial. - PARPi are recommended in the first line also to improve the risk-benefit ratio. - PARPi should be used cautiously in patients with a higher baseline risk and/or those who are less likely to have a significant benefit.
…
continue reading
4250 episodes
Alle afleveringen
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.